Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy

Vera Therapeutics, Inc.

UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.
eGFR stabilized in atacicept arm through week 24; Gd-IgA1 reduced robustly from baseline.
Safety well-tolerated: 1% discontinuation due to AEs, serious TEAEs 2% atacicept vs 9% placebo.
Company plans to advance atacicept into pivotal Phase 3 development in H1 2023 subject to FDA discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.